<DOC>
	<DOCNO>NCT02038335</DOCNO>
	<brief_summary>This study do understand use birth control cause change immune cell within reproductive tract healthy woman . Immune cell important help prevent infection start help fight infection start . Immune cell also type cell HIV ( human immunodeficiency virus ) infect understand help good understand prevent spread HIV . Immune cell study reproductive tract woman want start use one follow contraceptive : Depo-Provera ( DMPA ) , NET-EN , MPA/E2 ( Cyclofem速 ) , levonorgestrel subdermal implant ( Jadelle速 ) , etonogestrel subdermal implant ( Implanon速 Nexplanon速 ) copper IUD .</brief_summary>
	<brief_title>HIV-Target Cell Response Women Initiating Various Contraceptive Methods High HIV-Incidence Areas : Zim CHIC</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone enanthate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Age 18 34 year ( inclusive ) screen Nonpregnant woman general good health determine site clinician Premenopausal history regular menstrual cycle ( regular cycle define occur every 2135 day use hormones variation typical cycle length 5 day ) Able willing provide write informed consent screen take part study . Including willingness undergo studyrelated assessment follow studyrelated procedure Able willing provide adequate locator information HIVuninfected base test perform study staff screen At screen enrollment , agree participate research study involve drug , medical device , vaginal product enrol trial Use hormonal intrauterine contraceptive method within 30 day enrollment Use DMPA NETEN within 10 month enrollment Pregnancy breastfeeding within 60 day enrollment Surgical procedure involve pelvis 30 day prior enrollment ( include dilation curettage , cryosurgery biopsy vagina , vulva , cervix , endometrium ) Internal vaginal use device ( include sex toy , cervical cap , diaphragm , menstrual collection device , pessary ; excludes tampon condom ) product ( include N9 , microbicide , douche , antifungal , steroid , hormone ) 30 day prior enrollment New sexual partner within 90 day enrollment Urogenital infection suspect infection within 30 day enrollment include : symptomatic candidiasis , trichomoniasis , symptomatic BV ; cervical infection , include N. gonorrhoeae , Chlamydia trachomatis , mucopurulent cervicitis ; syphilis ; HSV lesion , sore ( Note : seropositive HSV without active lesion exclude ) ; acute pelvic inflammatory disease ; urinary tract infection ; recent exposure partner GC , CT , Trichomonas , syphilis , NGU . Women diagnose genital infection complete treatment least 30 day time enrollment . Any history immunosuppression ( include diabetes , HIV infection , chronic steroid use ) Antibiotic antifungal therapy ( vaginal systemic ) within 30 day enrollment Menses vaginal bleeding time Enrollment* ( *Women vaginal bleeding schedule Enrollment Visit may return different date reexamine possibly enrol provide still within 90day screen window meet criterion ) . Vaginal anal intercourse within 2 day ( 48 hour ) prior enrollment Heterosexual intercourse since last menses place participant risk pregnancy ( without condom use sterilization least one partner ) History hysterectomy History malignancy within pelvis ( include uterus , cervix , vagina , vulva ) Contraindication , allergy intolerance use contraceptive desire participant Any condition , opinion Investigator , would preclude provision consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>immune cell</keyword>
	<keyword>contraception</keyword>
	<keyword>intrauterine device</keyword>
	<keyword>IUD</keyword>
	<keyword>copper</keyword>
	<keyword>microbiota</keyword>
	<keyword>DMPA</keyword>
	<keyword>etonogestrel</keyword>
	<keyword>subdermal implant</keyword>
	<keyword>NET-EN</keyword>
	<keyword>Jadelle</keyword>
	<keyword>Implanon</keyword>
	<keyword>Cyclofem</keyword>
</DOC>